Why do older patients with advanced cancer decline participation in an exercise-based trial during oncological treatment? - A mixed methods study.

BACKGROUND: Exercise is recommended during anti-cancer treatments. However, there is lack of knowledge about existing barriers to participation in exercise-based trials, especially among understudied groups such as older patients and those with advanced cancer. OBJECTIVE: To explore reasons for refusal of participation in an exercise-based study among older patients with advanced cancer and identify factors associated with higher likelihood of declining. METHODS: A mixed methods design was applied, using qualitative data from interviews and quantitative data from medical records. We investigated potential differences in characteristics between patients who accepted and declined. Qualitative data underwent thematic analysis, and findings were synthesized to generate meta-inferences. RESULTS: Among 34 invited patients, 20 (59%) agreed to participate in the interviews, and 261 of 269 (97%) patients were included in quantitative analyses. Meta-inferences identified factors related to refusing exercise participation, including older age, perceptions of being sufficiently active, physical limitations, and awareness of having a poor prognosis. CONCLUSION: Refusal of participation was particularly related to advanced cancer, physical limitations, and older age. To address these barriers, it is recommended to adopt a holistic and supportive approach and improve the flexibility of recruitment strategies.

Risk of second cancers in patients with colorectal carcinoids.

INTRODUCTION: It is often stated that patients with colorectal carcinoid tumors have an increased risk of developing other malignancies. However, this risk has not been conclusively documented. A comprehensive evaluation is needed to more thoroughly assess the risk of second cancers in patients with colorectal carcinoids. METHODS: A search of the National Cancer Institute Surveillance, Epidemiology, and End Result database from 1973 to 1996 revealed 2,086 patients with colorectal carcinoids. This subset of patients was examined for occurrence of second cancers. The observed incidence of cancer for each site was compared with the expected incidence based on the gender-adjusted and age-adjusted cancer rates in the remaining Surveillance, Epidemiology, and End Result file. A Poisson distribution probability was used to determine the significance of these comparisons. RESULTS: Patients with colorectal carcinoids had an increased rate of cancer in the colon and rectum (P < 0.001), small bowel (P < 0.001), esophagus/stomach (P = 0.02), lung/bronchus (P < 0.001), urinary tract (P = 0.005), and prostate (P < 0.001), when compared with a control population. Most of the gastrointestinal tract cancers were synchronous cancers, whereas lesions outside the gastrointestinal tract were most commonly metachronous tumors. CONCLUSIONS: A significantly increased risk of synchronous colorectal, small-bowel, gastric, and esophageal cancers and metachronous lung, prostate, and urinary tract neoplasms is clearly demonstrated. After the diagnosis of colorectal carcinoid tumors, patients should undergo appropriate screening and surveillance for cancer at these sites.